MX2020011771A - Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. - Google Patents
Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.Info
- Publication number
- MX2020011771A MX2020011771A MX2020011771A MX2020011771A MX2020011771A MX 2020011771 A MX2020011771 A MX 2020011771A MX 2020011771 A MX2020011771 A MX 2020011771A MX 2020011771 A MX2020011771 A MX 2020011771A MX 2020011771 A MX2020011771 A MX 2020011771A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- combination therapy
- treatment
- antibodies against
- therapy involving
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 102000002029 Claudin Human genes 0.000 title 1
- 108050009302 Claudin Proteins 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 abstract 1
- 206010073069 Hepatic cancer Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 201000007487 gallbladder carcinoma Diseases 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 208000026037 malignant tumor of neck Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención proporciona una terapia de combinación para tratar y/o prevenir efectivamente enfermedades asociadas con células que expresan CLDN18.2, que incluyen enfermedades de cáncer tales como cáncer gástrico, cáncer esofágico, cáncer pancreático, cáncer pulmonar, cáncer de ovarios, cáncer de colon, cáncer hepático, cáncer de cabeza-cuello, y cáncer de la vesícula biliar y metástasis de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2012/002210 WO2013174403A1 (en) | 2012-05-23 | 2012-05-23 | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020011771A true MX2020011771A (es) | 2020-11-24 |
Family
ID=48483023
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014014216A MX2014014216A (es) | 2012-05-23 | 2013-05-21 | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. |
MX2020011782A MX2020011782A (es) | 2012-05-23 | 2014-11-21 | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. |
MX2020011780A MX2020011780A (es) | 2012-05-23 | 2014-11-21 | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. |
MX2019013723A MX2019013723A (es) | 2012-05-23 | 2014-11-21 | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. |
MX2020011771A MX2020011771A (es) | 2012-05-23 | 2014-11-21 | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014014216A MX2014014216A (es) | 2012-05-23 | 2013-05-21 | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. |
MX2020011782A MX2020011782A (es) | 2012-05-23 | 2014-11-21 | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. |
MX2020011780A MX2020011780A (es) | 2012-05-23 | 2014-11-21 | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. |
MX2019013723A MX2019013723A (es) | 2012-05-23 | 2014-11-21 | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. |
Country Status (26)
Country | Link |
---|---|
US (2) | US20150132253A1 (es) |
JP (2) | JP6203831B2 (es) |
KR (3) | KR102625189B1 (es) |
CN (2) | CN109172820B (es) |
AR (2) | AR091130A1 (es) |
AU (2) | AU2013265638B2 (es) |
BR (1) | BR112014028948B8 (es) |
CA (1) | CA2874032A1 (es) |
DK (2) | DK3791896T3 (es) |
ES (2) | ES2835073T3 (es) |
FI (1) | FI3791896T3 (es) |
HK (1) | HK1208152A1 (es) |
HR (2) | HRP20240169T1 (es) |
HU (2) | HUE054214T2 (es) |
IL (2) | IL235607A0 (es) |
LT (3) | LT3254695T (es) |
MX (5) | MX2014014216A (es) |
NZ (2) | NZ701585A (es) |
PL (1) | PL3791896T3 (es) |
PT (3) | PT3791896T (es) |
RS (2) | RS65179B1 (es) |
RU (1) | RU2665321C2 (es) |
SG (2) | SG11201406977TA (es) |
SI (2) | SI3254695T1 (es) |
UA (1) | UA118013C2 (es) |
WO (2) | WO2013174403A1 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10254601A1 (de) * | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
BR112015010740B1 (pt) | 2012-11-13 | 2024-01-30 | Biontech Ag | Agentes para tratamento de doenças cancerosas expressando claudina |
WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
WO2014146672A1 (en) | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
CN106460054A (zh) * | 2014-03-21 | 2017-02-22 | 新加坡科技研究局 | 癌症中的融合基因 |
WO2016180468A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Claudin-18.2-specific immunoreceptors and t cell epitopes |
MX2018015755A (es) | 2016-06-15 | 2019-08-29 | Icahn School Med Mount Sinai | Proteinas de hemaglutinina de virus de influenza y usos de las mismas. |
WO2018040537A1 (zh) * | 2016-08-31 | 2018-03-08 | 南京凯地生物科技有限公司 | 人pd-1基因敲除的cldn18.2 特异性嵌合抗原受体t细胞的制备方法以及应用 |
CA3058652A1 (en) | 2017-04-07 | 2018-10-11 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
EP3732190A1 (en) * | 2017-12-27 | 2020-11-04 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and methods of use thereof |
US10150801B1 (en) | 2017-12-27 | 2018-12-11 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and methods of use thereof |
EP3762031A4 (en) | 2018-03-08 | 2021-12-22 | Phanes Therapeutics, Inc. | ANTI-CLAUDINE ANTIBODIES 18.2 AND THEIR USES |
SG10202111141WA (en) * | 2018-05-18 | 2021-11-29 | Lanova Medicines Ltd Company | Anti-claudin 18.2 antibodies and uses thereof |
CN110857322A (zh) * | 2018-08-22 | 2020-03-03 | 瑞阳(苏州)生物科技有限公司 | 抗人claudin 18.2单克隆抗体及其应用 |
WO2020038404A1 (zh) * | 2018-08-22 | 2020-02-27 | 瑞阳(苏州)生物科技有限公司 | 抗人claudin 18.2单克隆抗体及其应用 |
KR20210072027A (ko) * | 2018-09-30 | 2021-06-16 | 카파 테라퓨틱스 리미티드 | Cldn18의 항체 및 화학요법 약물의 병용 요법 |
CA3118696A1 (en) * | 2018-11-08 | 2020-05-14 | The Uab Research Foundation | Compositions and methods for treating cancer |
JP2022515318A (ja) * | 2018-12-28 | 2022-02-18 | 四川科倫博泰生物医薬股▲フン▼有限公司 | 抗体及びその用途 |
JP2022515487A (ja) * | 2018-12-28 | 2022-02-18 | ナンジン、ジェンスクリプト、バイオテック、カンパニー、リミテッド | クローディン18.2結合部分およびその利用 |
JP2022528061A (ja) * | 2019-04-01 | 2022-06-08 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | 抗クローディン18.2抗体及びその用途 |
CA3137160A1 (en) * | 2019-04-24 | 2020-10-29 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
EP3978532A4 (en) * | 2019-05-24 | 2023-10-18 | Sanyou Biopharmaceuticals Co., Ltd. | NEW BINDING MOLECULE CLDN18.2 |
CA3147122A1 (en) * | 2019-07-12 | 2021-01-21 | Futuregen Biopharmaceutical (Beijing) Co., Ltd. | Cldn18.2 antibody and use thereof |
US10675332B1 (en) | 2019-08-26 | 2020-06-09 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and methods of use thereof |
KR20220161316A (ko) | 2020-03-30 | 2022-12-06 | 비온테크 에스이 | Claudin-18.2를 표적화하는 rna 조성물 |
WO2023025147A1 (zh) * | 2021-08-23 | 2023-03-02 | 南通壹宸生物医药科技有限公司 | 抗原表位修饰 |
CN114907482B (zh) * | 2021-09-03 | 2023-02-14 | 深圳市先康达生命科学有限公司 | 靶向人Claudin18.2蛋白的单克隆抗体及其应用 |
WO2023161457A1 (en) | 2022-02-27 | 2023-08-31 | Evobright Gmbh | Bispecific antibodies against cd277 and a tumor-antigen |
WO2024074634A1 (en) | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
WO2024074211A1 (en) | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
ATE378403T1 (de) | 2000-11-30 | 2007-11-15 | Medarex Inc | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
KR100932340B1 (ko) | 2002-10-17 | 2009-12-16 | 젠맵 에이/에스 | Cd20에 대한 인간 모노클로날 항체 |
US7217703B2 (en) * | 2004-04-16 | 2007-05-15 | Emisphere Technologies, Inc. | 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents |
EP1930414B1 (en) * | 2005-09-08 | 2012-07-18 | Medinet Co., Ltd. | Method for activation treatment of antigen-presenting cell |
EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
JPWO2008152822A1 (ja) * | 2007-06-15 | 2010-08-26 | 株式会社メディネット | 医薬 |
JP5596559B2 (ja) * | 2008-01-28 | 2014-09-24 | メディミューン リミテッド | 安定化アンジオポエチン2抗体とその用途 |
EP2316026A1 (en) * | 2008-07-25 | 2011-05-04 | Merck Patent GmbH | Method of determination of receptor binding saturation effected by monoclonal antibodies |
WO2010141093A2 (en) * | 2009-06-04 | 2010-12-09 | The University Of Maryland, Baltimore | Co-signaling methods for treating cancers |
WO2011090005A1 (ja) * | 2010-01-19 | 2011-07-28 | 協和発酵キリン株式会社 | 大腸癌の治療用医薬および治療方法 |
-
2012
- 2012-05-23 WO PCT/EP2012/002210 patent/WO2013174403A1/en active Application Filing
-
2013
- 2013-05-21 DK DK20194625.8T patent/DK3791896T3/da active
- 2013-05-21 DK DK13724523.9T patent/DK2852408T3/en active
- 2013-05-21 CA CA2874032A patent/CA2874032A1/en active Pending
- 2013-05-21 PT PT201946258T patent/PT3791896T/pt unknown
- 2013-05-21 CN CN201811066117.4A patent/CN109172820B/zh active Active
- 2013-05-21 CN CN201380026482.1A patent/CN104379166B/zh active Active
- 2013-05-21 LT LTEP17171169.0T patent/LT3254695T/lt unknown
- 2013-05-21 RU RU2014152115A patent/RU2665321C2/ru active
- 2013-05-21 LT LTEP13724523.9T patent/LT2852408T/lt unknown
- 2013-05-21 ES ES17171169T patent/ES2835073T3/es active Active
- 2013-05-21 SG SG11201406977TA patent/SG11201406977TA/en unknown
- 2013-05-21 ES ES13724523.9T patent/ES2637416T3/es active Active
- 2013-05-21 WO PCT/EP2013/001504 patent/WO2013174510A1/en active Application Filing
- 2013-05-21 RS RS20240147A patent/RS65179B1/sr unknown
- 2013-05-21 SI SI201331818T patent/SI3254695T1/sl unknown
- 2013-05-21 HU HUE17171169A patent/HUE054214T2/hu unknown
- 2013-05-21 HR HRP20240169TT patent/HRP20240169T1/hr unknown
- 2013-05-21 BR BR112014028948A patent/BR112014028948B8/pt active IP Right Grant
- 2013-05-21 LT LTEP20194625.8T patent/LT3791896T/lt unknown
- 2013-05-21 HU HUE13724523A patent/HUE036000T2/hu unknown
- 2013-05-21 SG SG10201609772PA patent/SG10201609772PA/en unknown
- 2013-05-21 UA UAA201413810A patent/UA118013C2/uk unknown
- 2013-05-21 KR KR1020217006323A patent/KR102625189B1/ko active IP Right Grant
- 2013-05-21 PT PT171711690T patent/PT3254695T/pt unknown
- 2013-05-21 NZ NZ701585A patent/NZ701585A/en not_active IP Right Cessation
- 2013-05-21 MX MX2014014216A patent/MX2014014216A/es active IP Right Grant
- 2013-05-21 RS RS20201449A patent/RS61127B1/sr unknown
- 2013-05-21 US US14/401,899 patent/US20150132253A1/en not_active Abandoned
- 2013-05-21 AU AU2013265638A patent/AU2013265638B2/en active Active
- 2013-05-21 JP JP2015513044A patent/JP6203831B2/ja active Active
- 2013-05-21 KR KR1020147036040A patent/KR102233344B1/ko active IP Right Grant
- 2013-05-21 NZ NZ725347A patent/NZ725347A/en unknown
- 2013-05-21 PT PT137245239T patent/PT2852408T/pt unknown
- 2013-05-21 FI FIEP20194625.8T patent/FI3791896T3/fi active
- 2013-05-21 KR KR1020247001045A patent/KR20240010757A/ko not_active Application Discontinuation
- 2013-05-21 SI SI201332076T patent/SI3791896T1/sl unknown
- 2013-05-21 PL PL20194625.8T patent/PL3791896T3/pl unknown
- 2013-05-22 AR ARP130101784 patent/AR091130A1/es not_active Application Discontinuation
-
2014
- 2014-11-10 IL IL235607A patent/IL235607A0/en active IP Right Grant
- 2014-11-21 MX MX2020011782A patent/MX2020011782A/es unknown
- 2014-11-21 MX MX2020011780A patent/MX2020011780A/es unknown
- 2014-11-21 MX MX2019013723A patent/MX2019013723A/es unknown
- 2014-11-21 MX MX2020011771A patent/MX2020011771A/es unknown
-
2015
- 2015-09-07 HK HK15108682.9A patent/HK1208152A1/xx unknown
-
2017
- 2017-08-30 JP JP2017165303A patent/JP6490764B2/ja active Active
-
2018
- 2018-02-27 AU AU2018201391A patent/AU2018201391B2/en active Active
- 2018-03-01 US US15/909,577 patent/US20180258180A1/en not_active Abandoned
-
2020
- 2020-11-23 HR HRP20201859TT patent/HRP20201859T1/hr unknown
- 2020-12-09 IL IL279330A patent/IL279330A/en unknown
-
2022
- 2022-05-17 AR ARP220101320A patent/AR125906A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020011796A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
MX2020011782A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
MX2017013075A (es) | Conjugados de farmaco que comprenden anticuerpos contra claudina 18.2. | |
MX2020011783A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
EP4242236A3 (en) | Monoclonal antibodies against claudin-18 for treatment of cancer | |
CY1123593T1 (el) | Συνδυαστικη θεραπεια που περιλαμβανει αντισωματα κλωντινης 18.2 για τη θεραπεια του καρκινου | |
JOP20220013A1 (ar) | علاج توليفي ينطوي على استخدام الأجسام المضادة ضد claudin 18.2 ومثبطات نقاط الفحص المناعي لعلاج السرطان | |
CR20230450A (es) | Terapia de combinación que implica anticuerpos contra claudina 18.2 para el tratamiento del cáncer |